Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...
Restaurants of the Year 2025 list, published today, features 44 restaurants that range from fine dining to supper clubs to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback